eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » Eli Lilly and Company - Comment

Eli Lilly and Company - Comment

Document ID: FDA-2008-D-0470-0004
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: October 16 2008, at 10:29 PM Eastern Daylight Time
Date Posted: October 16 2008, at 12:00 AM Eastern Standard Time
Comment Start Date: September 3 2008, at 12:00 AM Eastern Standard Time
Comment Due Date: October 20 2008, at 11:59 PM Eastern Standard Time
Tracking Number: 807615bd
View Document:  View as format xml

View Comment

ATTN: Dr. Abby Jacobs Eli Lilly and Company (Lilly) respectfully submits the following written comments regarding the 03 September 2008 Federal Register notice 73 FR 51491: “International Conference on Harmonisation; Draft Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals”.

Attachments:

Eli Lilly and Company - Comment

Title:
Eli Lilly and Company - Comment

View Attachment: View as format msw8

Eli Lilly and Company - Comment

Title:
Eli Lilly and Company - Comment

View Attachment: View as format msw8

Related Comments

    View All
Total: 9
Novo Nordisk Inc. - Comment
Public Submission    Posted: 10/15/2008     ID: FDA-2008-D-0470-0003

Oct 20,2008 11:59 PM ET
Eli Lilly and Company - Comment
Public Submission    Posted: 10/16/2008     ID: FDA-2008-D-0470-0004

Oct 20,2008 11:59 PM ET
Sanofi-aventis - Comment
Public Submission    Posted: 10/17/2008     ID: FDA-2008-D-0470-0005

Oct 20,2008 11:59 PM ET
Bristol-Myers Squibb Company - Comment
Public Submission    Posted: 10/17/2008     ID: FDA-2008-D-0470-0006

Oct 20,2008 11:59 PM ET
AstraZeneca - Comment
Public Submission    Posted: 10/20/2008     ID: FDA-2008-D-0470-0007

Oct 20,2008 11:59 PM ET